The UK’s MHRA halted sales of Novartis’s Tavneos, citing regulatory action that followed the EMA’s earlier decision, according to the report. In the same update stream, UniQure’s parallel push for Huntington’s gene therapy approval with UK regulators was also highlighted. For biotech and pharma operations, the Tavneos stop-sale underscores the speed at which European regulators can move to restrict marketed therapies, and how swiftly downstream commercial plans can be disrupted during rolling regulatory reviews.